Latest / Lung Cancer Considered
FDA Approval: Adjuvant Alectinib for Resected NSCLC
In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon discuss this development and take a deeper look at the ALINA trial, which played an important role in the drug's approval.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.